ResTORbio locks in $40 mln Series B
Boston-based ResTORbio Inc, a clinical-stage biopharmaceutical company focused on treating aging-related diseases, has closed $40 million in Series B financing. OrbiMed led the round with participation from other investors that included Fidelity Management & Research Company, Rock Springs Capital, Quan Capital and Nest Bio.
30 November 2017•1 min read
